Investigational drug · Phase 2
Isuzinaxib
Also called: APX-115
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Diabetic Kidney Disease (DKD), Contrast Induced Acute Kidney Injury.
Phase 2Last checked: Nov 20, 2026Latest source record: Aug 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
5
Any phase or sponsor naming "Isuzinaxib"
First trial start
2023
Dec 27, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Isuzinaxib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Diabetic Kidney Disease (DKD)
- Contrast Induced Acute Kidney Injury
Approved drugs for the same conditions: Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Isuzinaxib" as an intervention, largest first.
- Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCIPivotal-lookingCompleted
Aptabio Therapeutics, Inc.Industry
NCT05758896 · 218 participants · Start Dec 27, 2023 · Primary completion Jul 22, 2026
Drug: Isuzinaxib (APX-115); Placebo · For: Contrast Induced Acute Kidney Injury
Sites: Dallas, Texas; Chuncheon, South Korea; Daegu, South Korea · 14 sites in all
- Efficacy and Safety Study of Isuzinaxib in Subjects With DKDPivotal-lookingRecruiting
Aptabio Therapeutics, Inc.Industry
NCT06962098 · 186 participants (planned) · Start May 26, 2025 · Primary completion Jun 30, 2027
Drug: Isuzinaxib; Placebo · For: Diabetic Kidney Disease (DKD)
Sites: Ansan-si, South Korea; Busan, South Korea; Cheonan, South Korea · 20 sites in all
- Safety, Tolerability and Renal Effects of APX-115 in Subjects With Type 2 Diabetes and NephropathyPivotal-lookingCompleted
Aptabio Therapeutics, Inc.Industry
NCT04534439 · 140 participants · Start Aug 24, 2020 · Primary completion Jul 26, 2021
Drug: APX-115; Placebo · For: Diabetic Nephropathies; Diabetes Mellitus, Type 2; Nephropathy, Diabetic
Sites: Pleven, Bulgaria; Plovdiv, Bulgaria; Sliven, Bulgaria · 16 sites in all
Aptabio Therapeutics, Inc.Industry
NCT03694041 · 88 participants · Start May 28, 2018 · Primary completion Mar 6, 2019
Drug: SAD: APX-115; SAD: Placebo and 2 more · For: Healthy; Safety
Sites: Gières, France
- A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.Terminated
Aptabio Therapeutics, Inc.Industry
NCT04880109 · 16 participants · Start Oct 20, 2021 · Primary completion Apr 28, 2022
Drug: APX-115; Placebo · For: COVID-19
Sites: Little Rock, Arkansas; Annapolis, Maryland; Wyoming, Michigan · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Pharmacological Effects of NADPH Oxidase Inhibitors on Butterfly Wing Morphogenesis and Color Pattern Formation in Junonia orithya.
Nakazato Y, Ozaki M, Suenaga R, et al. · Insects 2026
- Targeting NADPH Oxidase with APX-115: Suppression of Platelet Activation and Thrombotic Response.
Jang J, Yu H, Oh EB, et al. · Antioxid Redox Signal 2025
- Pan-Nox inhibitor treatment improves renal function in aging murine diabetic kidneys.
Park JH, Yoon SG, Ghee JY, et al. · Kidney Res Clin Pract 2024
- Angiotensin II acts through Rac1 to upregulate pendrin: role of NADPH oxidase.
Pham TD, Verlander JW, Chen C, et al. · Am J Physiol Renal Physiol 2024
- Inhibition of NADPH Oxidases Prevents the Development of Osteoarthritis.
Han J, Park D, Park JY, et al. · Antioxidants (Basel) 2022
- APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice.
Lee ES, Kim HM, Lee SH, et al. · Free Radic Biol Med 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.